Efficacy and safety of once weekly semaglutide 2·4 mg for weight management in a predominantly east Asian population with overweight or obesity (STEP 7): a double-blind, multicentre, randomised controlled trial.

Mu Y, Bao X, Eliaschewitz FG, Hansen MR, Kim BT, Koroleva A, Ma RCW, Yang T, Zu N, Liu M

The lancet. Diabetes & endocrinology5 Feb 2024Cited by 102 (Europe PMC)

PMID38330988DOI10.1016/s2213-8587(23)00388-1PepBankPUB-38330988

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with overweight or obesity, semaglutide 2.4 mg reduced bodyweight by 12.1% versus 3.6% with placebo at week 44, a difference of 8.5 percentage points.
In plain wordsIn adults with overweight or obesity, semaglutide 2.4 mg led to more weight loss than placebo over 44 weeks.
Peptide
Semaglutide
Outcome
DecreasePercentage change in bodyweight to week 44
Study
n = 375
Comparator
Placebo
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Studied dose
2.4 mg · subcutaneous · 44 weeksAs given in this study (human).
Measurements
Mean bodyweight change
−12.1%
semaglutide 2.4 mg
Mean bodyweight change
−3.6%
placebo
Treatment difference
−8.5 percentage points
95% CI -10.2 to -6.8
Source sentences
Summary
Estimated mean percentage change in bodyweight from baseline to week 44 was -12·1% (SE 0·5) with semaglutide 2·4 mg versus -3·6% (0·7) with placebo (estimated treatment difference -8·5 percentage points [95% CI -10·2 to -6·8]; p<0·0001).
1 context sentence(design, population, supporting numbers)
Summary · context
Adults with overweight or obesity, with or without type 2 diabetes, were randomly assigned (2:1) to receive a subcutaneous injection of either semaglutide 2·4 mg or placebo once a week for 44 weeks, plus a diet and physical activity intervention.
Report a problemFND-3833098801
02HumanRandomized controlled trialEfficacy outcome
In adults with overweight or obesity, 85% lost at least 5% of bodyweight with semaglutide 2.4 mg versus 31% with placebo at week 44.
In plain wordsIn adults with overweight or obesity, more people lost at least 5% of body weight with semaglutide 2.4 mg than with placebo.
Peptide
Semaglutide
Outcome
IncreaseProportion with at least 5% bodyweight loss at week 44
Study
n = 354
Comparator
Placebo
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Studied dose
2.4 mg · subcutaneous · 44 weeksAs given in this study (human).
Measurements
Proportion with weight loss >=5%
85%
semaglutide 2.4 mg
Proportion with weight loss >=5%
31%
placebo
Odds ratio
13.1
95% CI 7.4-23.1
Source sentences
Summary
At week 44, the proportion of participants who lost 5% or more of their bodyweight was higher in the semaglutide 2·4 mg group than in the placebo group (203/238 [85%] vs 36/116 [31%]); odds ratio 13·1 (95% CI 7·4-23·1; p<0·0001).
1 context sentence(design, population, supporting numbers)
Summary · context
Adults with overweight or obesity, with or without type 2 diabetes, were randomly assigned (2:1) to receive a subcutaneous injection of either semaglutide 2·4 mg or placebo once a week for 44 weeks, plus a diet and physical activity intervention.
Report a problemFND-3833098802
03HumanRandomized controlled trialSafety outcome
In adults with overweight or obesity, adverse events were reported by 93% with semaglutide 2.4 mg and 86% with placebo.
In plain wordsIn adults with overweight or obesity, 93% on semaglutide 2.4 mg and 86% on placebo reported an adverse event.
Peptide
Semaglutide
Outcome
IncreaseAny adverse event
Study
n = 375
Comparator
Placebo
Outcome group
Adverse events · Whole body
Studied dose
2.4 mg · subcutaneous · 44 weeksAs given in this study (human).
Measurements
Participants with adverse events
93%
semaglutide 2.4 mg
Participants with adverse events
86%
placebo
Source sentences
Summary
Adverse events were reported by 231 (93%) of 249 participants in the semaglutide 2·4 mg group and 108 (86%) of 126 participants in the placebo group, the most common of which were gastrointestinal disorders (168/249, 67% vs 45/126, 36%).
1 context sentence(design, population, supporting numbers)
Summary · context
Adults with overweight or obesity, with or without type 2 diabetes, were randomly assigned (2:1) to receive a subcutaneous injection of either semaglutide 2·4 mg or placebo once a week for 44 weeks, plus a diet and physical activity intervention.
Report a problemFND-3833098803
04HumanRandomized controlled trialSafety outcome
In adults with overweight or obesity, gastrointestinal disorders occurred in 67% with semaglutide 2.4 mg versus 36% with placebo.
In plain wordsIn adults with overweight or obesity, stomach and bowel problems were more common with semaglutide 2.4 mg than with placebo.
Peptide
Semaglutide
Outcome
IncreaseGastrointestinal disorders
Study
n = 375
Comparator
Placebo
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
2.4 mg · subcutaneous · 44 weeksAs given in this study (human).
Measurements
Participants with gastrointestinal disorders
67%
semaglutide 2.4 mg
Participants with gastrointestinal disorders
36%
placebo
Source sentences
Summary
Adverse events were reported by 231 (93%) of 249 participants in the semaglutide 2·4 mg group and 108 (86%) of 126 participants in the placebo group, the most common of which were gastrointestinal disorders (168/249, 67% vs 45/126, 36%).
1 context sentence(design, population, supporting numbers)
Summary · context
Adults with overweight or obesity, with or without type 2 diabetes, were randomly assigned (2:1) to receive a subcutaneous injection of either semaglutide 2·4 mg or placebo once a week for 44 weeks, plus a diet and physical activity intervention.
Report a problemFND-3833098804

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT04251156

Research Study of How Well Semaglutide Works in People Living With Overweight or Obesity.

Novo Nordisk A/Sn = 3758 Dec 2020 to 23 Aug 2022

Overweight · Obesity · Diabetes Mellitus, Type 2

Trial page ClinicalTrials.govUpdated 29 Jan 2026

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 00:04 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.